BCR and acute lymphoblastic leukemia: Differences in NK cell activity among molecular ALL subtypes have been described, with increased NK cell-activating ligand expression (NKG2D and DNAM1) in patients with ALL carrying the fusion gene BCR-ABL (Philadelphia chromosome: Ph+), in contrast to Ph negatives (59).